Submitted by Nancy Lapid
(Reuters) -Novo Nordisk and Eli Lilly’s most popular weight loss medication should be the first medicines to treat doctors to treat obesity and its complications, the European Medical Association advised Thursday.
Semaglutid, the active Novo Wegovy and Ozempic and Tyzepatide, sold as Zepbound and Mounjar, Lilly, are so effective that they should be the first choice in almost all cases of large weight throws based on new European Associations for Natural Medicines.
Other medicines, including liraglutid, an older, less effective drug from the same class, naltrexone-taupropion and fentermin-topiramate, can be taken into account when it is necessary, including liraglutid, the guideline said.
Novo shares increased by 2.2% – 1007 GMT by surpassing European drug peers.
EASO guidelines are optional in individual countries.
Semaglutid, Tiurzepatide and other drugs from the class known as GLP-1 agonists completely change the care of obesity and its complications,-said Vallo D’Hebron University Hospital Barcelona, co-author Dr. Andreea Ciudin.
Although no treatment algorithm can change the nuanced clinical solution needed to fully care for patient care, new guidelines can help support the therapeutic solutions to obesity, she said.
Specific medicines for specific conditions
The authors of the guidelines analyzed the earlier results of the clinical trials, assessing the effects of the drug on weight loss, their safety profile and their effectiveness in specific complications.
Patients with physical excessive fat or adipose, tissue, thyzepatide effects should be considered as first -line treatment to solve obstructive sleep apnea and semaglutid for those with osteoarthritis knee.
In patients with obesity -related metabolic and immune dysfunctions, they recommend Semaglutid as the first choice for those with heart disease or stroke, thyzepatide in non -alcoholic fat liver disease, and thyzepatid or semaglutide in patients with prediabetes or Prediabete.
The drug class was originally developed for type 2 diabetes.
Although drugs are expensive and economic considerations are complex, the cost of obesity non-examination in the early stages “Thus, allowing progress to complications and organ damage should be equally assessed in health policy and clinical decision-making,” wrote guidelines.
Obesity management should not be limited to weight loss and its complications, but should be focused on enhanced mental well -being, physical fitness, social functioning, overall health and quality of life, they also said.
They acknowledge that most newer drugs have not been evaluated in the treatment of individual complications.
However, the authors say the effect of weight loss has been strongly linked to improvements of various complications, which increases the ability to positively affect their broader disorders such as chronic kidney disease, neurodegenerative diseases, polycystic ovary syndrome, and certain cancer and mental health conditions.
“Given the progress of the rapid treatment in the field of obesity treatment, EASO intends to regularly update the current treatment algorithm to incorporate the latest evidence,” Volkan Yumuk, a professor of president of the University of Istanbul University-Cerrahpaşa, said.
The American College of Medicine, American Nutrition Society, Obesity Medical Association and Obesity Society in June. At the same time, the treatment of GLP-1 should be accompanied by nutrition and lifestyle strategies.
“While GLP -1 alone can provide significant weight loss and related health benefits, several challenges limit long -term success for individuals and populations,” including gastrointestinal side effects, nutrient deficiencies, muscle and bone throwing, high costs, frequent termination and weight recovery, “said the advice.
(Nancy Lapid messages; edited by Caroline Humer, Bill Berkrot and Louise Heavens)